Track LUCD and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$98.89M
Enterprise Value-$34.58B
Revenue (TTM)$4.71M
Net Income (TTM)-$58.01M
Free Cash Flow (TTM)-$46.68M
Financial Health
Cash$34.70B
Net Debt-$34.68B
Debt Ratio0.62
Debt to Equity2.28
Interest Coverage-7.03
Valuation (TTM)
Price to Sales21.01
Price to Earnings-1.7
EV to EBITDA615
Price to Book9.04
Price to Free Cash Flow-2.12
Margins (TTM)
Gross Profit Margin-55.59%
EBITDA Margin-1194.86%
Operating Income Margin-1054.82%
Net Income Margin-1232.68%
Free Cash Flow Margin-991.97%
Returns (5Y Avg)
Return on Invested Capital-2365.23%
Return on Assets-4082.25%
Return on Equity121.78%
Return on Total Capital-2365.23%
Return on Capital Employed190.67%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue1000.00%
Diluted EPS-3.23%
Total Debt1000.00%
Capital Expenditures-25.56%
Free Cash Flow-99.26%
CAGR (3Y)
Revenue131.97%
Diluted EPS24.62%
Total Debt875.50%
Capital Expenditures-39.91%
Free Cash Flow-99.97%
CAGR (1Y)
Revenue8.28%
Diluted EPS22.00%
Total Debt1000.00%
Capital Expenditures-69.50%
Free Cash Flow-100.00%
$0.97-$0.00|-0.27%
52W High$1.63
52W Low$0.90
50D SMA$1.02
200D SMA$1.15
Volume1.24M
Lucid Diagnostics Inc
360 Madison Avenue, New York, NY, United States, 10017
IPO
2021
Employees
82
Industry
Medical Devices
Sector
Healthcare
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20250+1
1
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0